COMPASS Pathways (NASDAQ:CMPS) Rating Reiterated by Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of COMPASS Pathways (NASDAQ:CMPS) in a report issued on Thursday, Benzinga reports.

A number of other equities analysts have also recently commented on the stock. Morgan Stanley assumed coverage on shares of COMPASS Pathways in a report on Monday, April 1st. They issued an overweight rating and a $30.00 target price on the stock. HC Wainwright reissued a buy rating and set a $120.00 price objective on shares of COMPASS Pathways in a research report on Friday, March 1st. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of Buy and a consensus target price of $47.40.

COMPASS Pathways Stock Performance

Shares of CMPS stock opened at $8.42 on Thursday. The stock’s 50-day moving average is $9.98 and its two-hundred day moving average is $8.34. The company has a quick ratio of 13.33, a current ratio of 13.33 and a debt-to-equity ratio of 0.14. COMPASS Pathways has a 1 year low of $5.01 and a 1 year high of $12.75.

COMPASS Pathways (NASDAQ:CMPS) last released its quarterly earnings results on Thursday, February 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.16). As a group, sell-side analysts forecast that COMPASS Pathways will post -2.4 earnings per share for the current year.

Insider Activity

In related news, Director Ekaterina Malievskaia sold 19,853 shares of the stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $10.59, for a total transaction of $210,243.27. Following the completion of the sale, the director now directly owns 4,144,994 shares of the company’s stock, valued at $43,895,486.46. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other news, Director George Jay Goldsmith sold 15,740 shares of COMPASS Pathways stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $10.58, for a total value of $166,529.20. Following the sale, the director now owns 4,079,107 shares of the company’s stock, valued at $43,156,952.06. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Ekaterina Malievskaia sold 19,853 shares of the business’s stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $10.59, for a total transaction of $210,243.27. Following the transaction, the director now owns 4,144,994 shares in the company, valued at $43,895,486.46. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 166,351 shares of company stock valued at $1,553,923. Company insiders own 23.99% of the company’s stock.

Institutional Investors Weigh In On COMPASS Pathways

Hedge funds have recently added to or reduced their stakes in the company. Quest Partners LLC acquired a new stake in COMPASS Pathways in the fourth quarter valued at about $33,000. UBS Group AG lifted its position in COMPASS Pathways by 249.1% in the fourth quarter. UBS Group AG now owns 4,291 shares of the company’s stock valued at $34,000 after purchasing an additional 3,062 shares during the period. Quantbot Technologies LP lifted its position in COMPASS Pathways by 156.8% in the first quarter. Quantbot Technologies LP now owns 3,338 shares of the company’s stock valued at $43,000 after purchasing an additional 2,038 shares during the period. Advisor Group Holdings Inc. lifted its position in COMPASS Pathways by 129.7% in the fourth quarter. Advisor Group Holdings Inc. now owns 5,406 shares of the company’s stock valued at $43,000 after purchasing an additional 3,052 shares during the period. Finally, Tower Research Capital LLC TRC lifted its position in COMPASS Pathways by 229.6% in the third quarter. Tower Research Capital LLC TRC now owns 7,847 shares of the company’s stock valued at $58,000 after purchasing an additional 5,466 shares during the period. Institutional investors and hedge funds own 46.19% of the company’s stock.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.